Varicella zoster immune globulin (human) (VARIZIG) in immunocompromised patients: a subgroup analysis for safety and outcomes from a large, expanded-access program

Table 3 Safety in immunocompromised adults

Preferred term	Type of immune-compromising condition, n (%)
Preferred term	All (n = 40)	Primary immunodeficiency^a (n = 6)	Oncologic immunodeficiency^b (n = 10)	Solid organ transplant^c (n = 5)	Hematopoietic cell transplant^d (n = 6)	Other^e (n = 13)
AEs
Participants, n (%)	15 (38)	3 (50)	2 (20)	1 (20)	3 (50)	6 (46)
Total AEs, n	51	5	3	1	29	13
Total related AEs, n	1	0	1	0	0	0
All related AEs, n (%)
Nausea	1 (3)	0	1 (10)	0	0	0
Serious AEs
Participants, n (%)	4 (10)	1 (17)	1 (10)	0	0	2 (15)
Total serious AEs, n	10	1	2	0	0	7
Total related serious AEs, n	0	0	0	0	0	0
Deaths, n (%)^f	1 (3)	1 (17)	0	0	0	0

^aIncludes participants with primary immunodeficiencies (e.g. HIV infection/AIDS, hypogammaglobulinemia, immunodeficiency common variable)
^bIncludes participants with oncologic immunodeficiencies
^cIncludes participants who have undergone SOT and are taking anti-rejection medication
^dIncludes participants who have undergone HCT
^eIncludes participants with other immunocompromising conditions (e.g. multiple sclerosis, lupus nephritis, adrenoleukodystrophy, chronic renal failure, asthma, juvenile-onset arthritis)
^fDeath was due to respiratory failure in a woman with AIDS; death was considered unrelated to varicella or VARIZIG

ISSN: 1471-2334